MDT
86.56
+0.83%↑
A
113.95
+1.74%↑
VEEV
175.31
+0.07%↑
HQY
83.18
+1.87%↑
PHR.US
8.32
-27.08%↓
MDT
86.56
+0.83%↑
A
113.95
+1.74%↑
VEEV
175.31
+0.07%↑
HQY
83.18
+1.87%↑
PHR.US
8.32
-27.08%↓
MDT
86.56
+0.83%↑
A
113.95
+1.74%↑
VEEV
175.31
+0.07%↑
HQY
83.18
+1.87%↑
PHR.US
8.32
-27.08%↓
MDT
86.56
+0.83%↑
A
113.95
+1.74%↑
VEEV
175.31
+0.07%↑
HQY
83.18
+1.87%↑
PHR.US
8.32
-27.08%↓
MDT
86.56
+0.83%↑
A
113.95
+1.74%↑
VEEV
175.31
+0.07%↑
HQY
83.18
+1.87%↑
PHR.US
8.32
-27.08%↓
24h
Corrente
Minimo
65.17
Massimo
72.57
Entrata | -557K -36M |
|---|---|
Vendite | 10M 22M |
EPS | -1.29 |
Margine di Profitto | -165.447 |
Dipendenti | 63 |
EBITDA | 10M -19M |
Raccomandazioni | Fortemente da comprare |
|---|---|
Previsioni per 12 mesi | +82.16% upside |
Utili prossimi | 7 mag 2026 |
|---|
Capitalizzazione di Mercato | 198M 2.1B |
|---|---|
Apertura precedente | 61.57 |
Chiusura precedente | 71.71 |
By Trading Central
Fiducia
Strong Bearish Evidence
0.5949 / 0.7406 Supporto e resistenza
Le prestazioni passate non sono un indicatore affidabile dei risultati futuri.
31 mar 2026, 23:31 UTC
Stocks to Watch: Nike, RH, NCino
DJ
LeggI
31 mar 2026, 22:35 UTC
Nike Guides for Sales Declines Ahead as Turnaround Plan Hits Snags -- 2nd Update
DJ
LeggI
1 apr 2026, 00:00 UTC
The Year Is Off to the Strongest Start for Big Deals Ever -- WSJ
DJ
LeggI
31 mar 2026, 23:50 UTC
Nxera Pharma: Partner Centessa Pharmaceuticals to Be Acquired by Lilly >LLY 4565.TO
DJ
LeggI
31 mar 2026, 23:43 UTC
Nikkei May Rise on Hopes for Iran War Ending Soon -- Market Talk
DJ
LeggI
31 mar 2026, 23:33 UTC
Gold Edges Higher on Signs of De-Escalating Middle East Tensions -- Market Talk
DJ
LeggI
31 mar 2026, 23:21 UTC
Nike Stock Slides on Tariff Impact Despite Earnings Beat; Turnaround Continues -- Barrons.com
DJ
LeggI
31 mar 2026, 23:14 UTC
Nike CEO Says Turnaround is Taking Longer Than He'd Like -- Market Talk
DJ
LeggI
31 mar 2026, 23:12 UTC
Aurelia's Cash Flow Strength Highlighted by New Financing Deal -- Market Talk
DJ
LeggI
31 mar 2026, 22:36 UTC
China Vanke 2025 Loss Widens >000002.SZ
DJ
LeggI
31 mar 2026, 22:36 UTC
China Vanke: Increase in Inventory Impariment Provision Among Factors Weighing On Results>000002.SZ
DJ
LeggI
31 mar 2026, 22:36 UTC
China Vanke 2025 Loss CNY88.56B Vs. Loss CNY49.48B >000002.SZ
DJ
LeggI
31 mar 2026, 22:36 UTC
China Vanke: Will Take Time to Resolve Issues Caused by High Debt Levels>000002.SZ
DJ
LeggI
31 mar 2026, 22:36 UTC
China Vanke 2025 Rev CNY233.43B Vs. CNY343.18B >000002.SZ
DJ
LeggI
31 mar 2026, 21:46 UTC
Big Drug Companies Hunting for Deals Are Lowering Their Sights -- WSJ
DJ
LeggI
31 mar 2026, 21:36 UTC
West African Resources's Costs Higher Than Bull Expected -- Market Talk
DJ
LeggI
31 mar 2026, 21:35 UTC
Nike Expects China Sales Down 20% in 4Q, CFO Says
DJ
LeggI
31 mar 2026, 21:35 UTC
Nike Expects Modest Growth in North America, Offset by Declines in China, Converse Brand in 4Q, CFO Says
DJ
LeggI
31 mar 2026, 21:35 UTC
Nike Forecasts 4Q Sales Down 2% to 4%, CFO Says
DJ
LeggI
31 mar 2026, 21:33 UTC
Biotechs Are a Healthy Growth Bet Thanks to M&A and New Drugs -- Barrons.com
DJ
LeggI
31 mar 2026, 21:33 UTC
Nike Expects Sales Down Low-Single Digits From Now Through End of Calendar Year, CFO Says
DJ
LeggI
31 mar 2026, 21:32 UTC
Nike Expects 1Q to Be Final Quarter Where Tariffs Continue to Be Year-Over-Year Headwind to Margins, CFO Says
DJ
LeggI
31 mar 2026, 21:28 UTC
Nike Expects to End 4Q With Elevated Inventory, CFO Says
DJ
LeggI
31 mar 2026, 21:26 UTC
Nike Increasingly Confident It Will Return to Balanced Growth in North America in Direct, Wholesale Channels, CFO Says
DJ
LeggI
31 mar 2026, 21:25 UTC
Nike Expects Supply-Chain Changes to Pay Off Starting in Fiscal 2027, CFO Says
DJ
LeggI
31 mar 2026, 21:24 UTC
Nike: Turnaround Plan Progressing at Different Rates -- Market Talk
DJ
LeggI
31 mar 2026, 21:22 UTC
Nike CFO Expects Football Training and Basketball Will Return to Growth Over Next Few Quarters
DJ
LeggI
31 mar 2026, 21:22 UTC
Nike's Sportswear Business Declined Low-Double Digits in 3Q, CFO Says
DJ
LeggI
31 mar 2026, 21:21 UTC
Nike's Digital Channel Still Too Promotional, CFO Says
DJ
LeggI
31 mar 2026, 21:20 UTC
Nike CEO: Converse Remains Important to Portfolio
DJ
LeggI
Modifica del prezzo
By TipRanks
Previsioni per 12 mesi
Media 118.86 USD 82.16%
Alto 165 USD
Basso 68 USD
Basato su 8 analisti di Wall Street che offrono Obiettivi di Prezzo a 12 mesi per Nektar Therapeutics - Dist negli ultimi 3 mesi.
By TipRanks
Fortemente da comprare
8 ratings
7
Acquista
1
Mantieni
0
Vendi
Basato sugli analisti di 8 che hanno fornito valutazioni azionarie a Nektar Therapeutics - Dist negli ultimi 3 mesi.
By Trading Central
A breve termine
Strong Bearish Evidence
Recent bearish events outweigh bullish events.
A termine intermedio
Strong Bearish Evidence
All events are bearish.
A lungo termine
Bearish Evidence
All events are bearish.
Spese di vendita e di amministrazione
Spese operative
Utile prima delle imposte
Vendite
Costo delle vendite
Utile lordo sulle vendite
Interessi passivi sul debito
EBITDA
Utile operativo
$